MedTrace Logo

Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers

NCT00941018 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2009-12-02

No results posted yet for this study

Summary

This study is being conducted to determine the safety, tolerability, pharmacodynamics and pharmacokinetics of RX-10001.

Conditions

  • Healthy

Interventions

DRUG

RX-10001

RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.

Sponsors & Collaborators

  • Resolvyx Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Renger Tiessen, MD PhD · PRA Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941018 on ClinicalTrials.gov